Dr. Kaufman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1365 Clifton Rd Ne
Atlanta, GA 30322Phone+1 404-778-1900Fax+1 404-778-3260
Summary
- Jonathan Kaufman, MD is an oncologist based in Atlanta, GA, with a subspecialty in hematologic oncology. He completed his fellowship and residency at Emory University School of Medicine after graduating from the Medical College of Georgia at Augusta University in 1999. Dr. Kaufman has extensive experience in treating conditions like pancreatic cancer, al amyloidosis, and multiple myeloma, among others. He has several medical publications to his name, all related to his specialties, and he has led clinical trials as the Principal Investigator, including trials focusing on treatments for relapsed or refractory multiple myeloma.
Education & Training
- Emory University School of MedicineFellowship, Hematology and Medical Oncology, 2001 - 2005
- Emory University School of MedicineResidency, Internal Medicine, 1999 - 2001
- Medical College of Georgia at Augusta UniversityClass of 1999
Certifications & Licensure
- GA State Medical License 2003 - 2025
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma Start of enrollment: 2022 Oct 19
Roles: Principal Investigator, Contact
- A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2017 Oct 04
Roles: Principal Investigator
Publications & Presentations
PubMed
- 120 citationsGain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.Timothy M. Schmidt, Benjamin G. Barwick, Nisha Joseph, Leonard T. Heffner, Craig C. Hofmeister
Blood Cancer Journal. 2019-11-25 - 5 citationsDaratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.Natalie S Callander, Rebecca Silbermann, Jonathan L Kaufman, Kelly N Godby, Jacob Laubach
Blood Cancer Journal. 2024-04-22 - 33 citationsSubcutaneous Versus Intravenous Bortezomib Efficiency Practice Variables and Patient PreferencesMeagan S. Barbee, R. Donald Harvey, Sagar Lonial, Jonathan L. Kaufman, N.M. Wilson
The Annals of Pharmacotherapy. 2013-09-01
Abstracts/Posters
- Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...Jonathan L. Kaufman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple ...Jonathan L. Kaufman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrang...Jonathan L. Kaufman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Challenges in Myeloma Therapy61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed ...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Updated subgroup analysis of POLLUX based...2019 ASCO Annual Meeting - 6/1/2019
- Join now to see all
Press Mentions
- Jonathan Kaufman, MD, Talks Targeting BCL-2 with Venetoclax and Dexamethasone in R/R MMMay 12th, 2021
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: